Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leiomyoma | D007889 | HP_0000131 | D25 | — | 3 | 6 | — | — | 9 |
Myofibroma | D047708 | — | — | — | 3 | 6 | — | — | 9 |
Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | 6 | — | — | 6 |
Metrorrhagia | D008796 | HP_0100608 | N92.1 | — | — | 6 | — | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Endometriosis | D004715 | EFO_0001065 | N80 | — | 3 | — | — | — | 3 |
Postmenopause | D017698 | — | — | — | 2 | — | — | — | 2 |
Amenorrhea | D000568 | — | N91.2 | — | 1 | — | — | — | 1 |
Drug common name | Asoprisnil |
INN | asoprisnil |
Description | Asoprisnil (INN; developmental code name J-867) is a synthetic, steroidal selective progesterone receptor modulator that was under development by Schering and TAP Pharmaceutical Products for the treatment of uterine fibroids. In 2005, phase III clinical trials were discontinued due to endometrial changes in patients.
|
Classification | Small molecule |
Drug class | steriodal compounds acting on progesterone receptors (excluding-gest- compounds); selective progesterone receptor modulators (SPRM) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COC[C@]1(OC)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(/C=N/O)cc3)C[C@@]21C |
PDB | — |
CAS-ID | 199396-76-4 |
RxCUI | — |
ChEMBL ID | CHEMBL267431 |
ChEBI ID | — |
PubChem CID | 9577221 |
DrugBank | — |
UNII ID | 72W09924WP (ChemIDplus, GSRS) |